Navigation Links
Ambry Genetics Launches First X-Linked Mental Retardation Diagnostics Using Next Generation Sequencing
Date:3/23/2010

ALISO VIEJO, Calif., March 23 /PRNewswire/ -- Ambry Genetics today introduced The Ambry X-Linked Mental Retardation SuperPANEL™, a suite of genetic tests expected to pinpoint the cause of intellectual disability and X-linked mental retardation (XLMR).  This panel marks the first time next generation sequencing technology, coupled with microarrays, Sanger sequencing and traditional Fragile X testing, is being made clinically available to address this disorder, giving physicians a full range of reflex options to suit the needs of their patients.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090428/LA06744LOGO)

The Ambry XLMR SuperPANEL spans all levels of genetic resolution, from genome-wide scan through focused study of the X chromosome to base-pair analysis of approximately ninety specific target genes.  Components include the XLMR Array Plus™, the XLMR Next Gen Sequencing Panel, and individual sequencing tests including Fragile X.  Testing can be customized for individual patients.  The Sequencing Panel uses new and innovative technologies, including RainDance Technologies' RDT 1000 system for sequence enrichment with the Illumina Genome Analyzer IIx.  Ambry has been an Illumina Certified Service Provider for research services since 2007.

"I'm very excited about the various technologies we applied to this suite of tests, and that we can develop similar tests for other complex disease states," said Anja Kammesheidt, Chief Scientific Officer at Ambry Genetics. "The new technologies create an important paradigm shift and allow us to comprehensively investigate complex genetic disorders in the same way monogenic disorders have been diagnosed for years."

"Ambry Genetics is ideally suited to bring multigenic assays into the marketplace," said Charles Dunlop, Chief Executive Officer.  "We've not only been performing services on these platforms for years with a very good understanding of the nuances of these technologies, but we also have over a decade of experience launching high information-content sequencing tests.  We know how to deal with the interpretation issues that arise at the patient level, and our company is geared towards helping physicians with this type of information."

About Ambry Genetics

Ambry Genetics is a CAP-accredited, CLIA-certified commercial clinical laboratory headquartered in Aliso Viejo, California. Established in 2000, it is a recognized leader in diagnostic and contract genomic services.  Ambry specializes in the application of new technologies to molecular diagnostics and genetics research. To learn more, visit www.ambrygen.com.

About Intellectual Disability and X-Linked Mental Retardation

Intellectual disability (also called mental retardation) is a lifelong impairment of cognitive and adaptive skills affecting approximately 2-3% of the general population.  For approximately half of patients who have undergone extensive traditional evaluations, the cause remains unknown.  About 10-15% of intellectual disability is attributed to genetic defects of the X chromosome and is called X-linked mental retardation (XLMR).  XLMR affects as many as 1/1000 to 1/600 males plus a significant number of females.  Extensive information about intellectual disability is available from the American Association on Intellectual and Developmental Disabilities at www.aaidd.org.

SOURCE Ambry Genetics

Back to top

RELATED LINKS
http://www.ambrygen.com
http://www.aaidd.org

'/>"/>

SOURCE Ambry Genetics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ambry Genetics Announces Certified Service Provider Status for Agilent Microarrays
2. Ambry Genetics Announces the Addition of Array CGH Services Through Partnership With Baylor College of Medicine
3. DuPont to Expand Plant Genetics Research Facilities
4. Interleukin Genetics to Present at the 12th Annual BIO CEO Conference
5. Molecular Genetics Core Facility at Childrens Hospital Boston Selects HybSelect from febit for Targeted Resequencing
6. deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court
7. New Appointments at London Genetics to Drive Strategy Forward
8. Viral Genetics Lead Scientist Dr. M. Karen Newell Will Present at 11th Annual SoCalBio Investor and Partnership Conference
9. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
10. Viral Genetics Responds to Rumors of Imminent FDA Filing and Third Party Press Releases
11. Interleukin Genetics Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... 2017 SomaGenics announced the receipt of a ... RealSeq®-SC (Single Cell), expected to be the first commercially ... microRNAs) from single cells using NGS methods. The NIH,s ... accelerate development of approaches to analyze the heterogeneity of ... techniques for measuring levels of mRNAs in individual cells ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree Wellness ... targeting the needs of consumers who are incorporating medical marijuana into their wellness ... Arizona. , As operators of two successful Valley dispensaries, The Giving Tree’s two ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first ... accompanying cloud-based bioinformatics software to perform Hi-C metagenome deconvolution using their own ...
Breaking Biology Technology:
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... March 30, 2017 Trends, opportunities and forecast ... behavioral), by technology (fingerprint, AFIS, iris recognition, facial recognition, ... others), by end use industry (government and law enforcement, ... and banking, and others), and by region ( ... Asia Pacific , and the Rest ...
Breaking Biology News(10 mins):